PET/CT与三联内镜在HPV阳性口咽鳞状细胞癌初始检查中的比较
单机构回顾性分析65例HPV阳性口咽鳞状细胞癌患者,评估三联内镜与PET/CT检出同时性原发肿瘤的效果。PET/CT检出1例(1.5%)同时性原发肿瘤,三联内镜未检出。PET/CT敏感度100%、特异度95.3%,阳性预测值25.0%、阴性预测值100%;三联内镜特异度90.2%、阴性预测值93.2%。作者认为PET/CT在排除同时性原发肿瘤方面优于三联内镜。
要点
- 65例HPV阳性口咽鳞癌患者中,PET/CT检出同时性原发肿瘤1例(1.5%),三联内镜未检出。
- PET/CT敏感度100%、特异度95.3%,阴性预测值100%。
- 三联内镜特异度90.2%、阴性预测值93.2%。
核心结论
- 作者认为,PET/CT在排除同时性原发肿瘤方面优于三联内镜;当PET/CT阴性时,可能仅需行直接喉镜检查加活检。
研究设计与样本
- 单机构回顾性研究,纳入65例HPV阳性口咽鳞状细胞癌患者,评估三联内镜与PET/CT的检查效果。
主要发现
- 65例患者中,白人48例(72.7%),男性53例(81.5%),平均年龄58.7±8.1岁。
- PET/CT检出同时性原发肿瘤1例(1.5%),三联内镜未检出同时性原发肿瘤。
- PET/CT敏感度100%、特异度95.3%,阳性预测值25.0%、阴性预测值100%。
- 三联内镜特异度90.2%、阴性预测值93.2%。
关键数值与推荐
- PET/CT检出同时性原发肿瘤1例(1.5%),三联内镜检出0例。
- PET/CT敏感度100%、特异度95.3%、阳性预测值25.0%、阴性预测值100%。
- 三联内镜特异度90.2%、阴性预测值93.2%。
临床怎么用
- 作者认为,PET/CT在排除同时性原发肿瘤方面优于三联内镜。
- 作者认为,当PET/CT阴性时,可能仅需行直接喉镜检查加活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Synchronous primary tumors (SPTs) are detected via triple endoscopy or positron emission tomography/computed tomography (PET/CT). Patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) lack risk factors for SPTs. METHODS: We performed a single institution retrospective review of the efficacy of triple endoscopy and PET/CT in HPV+ OPSCC patients. RESULTS: Sixty-five HPV+ OPSCC patients underwent triple endoscopy and PET/CT. Patients were white (n = 48, 72.7%), male (n = 53, 81.5%), mean 58.7 ± 8.1 years old. SPT was detected in 1 (1.5%) patient via PET/CT. No SPTs were detected on triple endoscopy. PET/CT had 100% and 95.3% sensitivity and specificity, respectively. PET/CT positive predictive value (PPV) and negative predictive value (NPV) were 25.0% and 100%, respectively. Triple endoscopy specificity and NPV was 90.2% and 93.2%, respectively. CONCLUSIONS: PET/CT is superior to triple endoscopy in ruling out SPTs. With negative PET/CT, only direct laryngoscopy with biopsy may be necessary.
引用
- Muller RG, Weidenbecher M, Ludlow D, et al. PET/CT versus triple endoscopy in initial workup of HPV+ oropharyngeal squamous cell carcinoma. Head Neck. 2022. PMID: 35212072. doi:10.1002/hed.27016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。